Health ❯Healthcare ❯Diabetes ❯Type 2 Diabetes

Treatment Options

Adverse Effects Drug Safety Chronic Conditions Pharmacology Clinical Trials Medications Emerging Markets Public Health Market Competition Side Effects

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials